Study comparing the clinical outcomes of 3 different P2Y12 inhibitors (Clopidogrel, Ticagrelor and Prasugrel) in patients with Atrial Fibrillation treated with DATP after Acute Myocardial Infaction with Percutaneous Coronary Intervention: Korean AMI Registry (KAMIR)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 15 Apr 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Clopidogrel (Primary) ; Prasugrel (Primary) ; Ticagrelor (Primary)
Indications Acute coronary syndromes; Myocardial infarction; Stroke
Focus Therapeutic Use

Most Recent Events

01 Mar 2019 Results (n=3985, patients with MI and diabetes who underwent PCI enrolled between November 2011 and December 2015) published in the Medicine
19 Sep 2018 New trial record
29 Aug 2018 Results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight